Scancell (LON:SCLP) Trading Up 29.8% – Should You Buy?

Scancell Holdings plc (LON:SCLP) shares shot up 29.8% during mid-day trading on Monday . The stock traded as high as GBX 11.38 ($0.15) and last traded at GBX 11 ($0.15). 10,537,342 shares changed hands during trading, an increase of 1,073% from the average session volume of 897,982 shares. The stock had previously closed at GBX 8.48 ($0.11).

Scancell Trading Up 29.8 %

The stock has a market cap of £113.93 million, a P/E ratio of -16.86 and a beta of 0.35. The firm’s 50-day simple moving average is GBX 8.43 and its 200 day simple moving average is GBX 10.88. The company has a current ratio of 3.42, a quick ratio of 13.01 and a debt-to-equity ratio of -566.79.

Scancell (LON:SCLP) last announced its quarterly earnings data on Thursday, January 30th. The company reported GBX (1.35) (($0.02)) earnings per share (EPS) for the quarter. As a group, equities research analysts anticipate that Scancell Holdings plc will post -2.5361112 earnings per share for the current year.

Scancell Company Profile

Scancell (LSE:SCLP) is a clinical stage immunotherapy biotech company developing treatments for significant unmet needs in cancer. We aim to translate our innovation and creativity into increased and durable responses in patients without compromising safety, addressing hard-to-treat cancers.

Scancell has developed a pipeline of ‘off-the-shelf’ vaccines to induce immune responses and highly tumour specific monoclonal antibodies to redirect immune cells or drugs.